Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26421485 | 0.88 | APP (0.32) | APP | |
| SCHEMBL16666124 | 0.81 | APP (0.35) | APPEPHX2 | |
| SCHEMBL16724858 | 0.76 | LMNA (0.38) | APP | |
| SCHEMBL31181874 | 0.75 | BBOX1 (0.43) | APPEPHX2 | |
| SCHEMBL9165713 | 0.72 | SLC22A1 (0.46) | APPEPHX2 | |
| SCHEMBL15965937 | 0.72 | SLC22A1 (0.55) | APPEPHX2 | |
| Tetrabuthylammonium SCHEMBL4608034 | 0.71 | SLC22A1 (0.43) | APPEPHX2 | |
| SCHEMBL12109955 | 0.71 | SLC22A1 (0.56) | EPHX2 | |
| SCHEMBL28558958 | 0.71 | SLC22A1 (0.56) | EPHX2 | |
| SCHEMBL11244311 | 0.70 | APP (0.42) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284439-A1 | NEAR INFRARED PHOTOIMMUNOTHERAPY (NIR-PIT) COMBINATION THERAPY TO TREAT CANCER | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-4279494-A1 | METHOD FOR DECOMPOSING COMPOUND, AND COMPOUND | National University Corporation Hokkaido University (JP) | 2023-11-22 | — | — | EP | disclosed |
| US-20230218761-A1 | METHOD FOR DECOMPOSING COMPOUND AND COMPOUND | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2023-07-13 | — | — | US | disclosed |
| WO-2022165277-A1 | NEAR INFRARED PHOTOIMMUNOTHERAPY (NIR-PIT) COMBINATION THERAPY TO TREAT CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2022131054-A1 | METHOD FOR DECOMPOSING COMPOUND, AND COMPOUND | 国立大学法人北海道大学 | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218761-A1 | METHOD FOR DECOMPOSING COMPOUND AND COMPOUND | RPS21, RPS14, F11 | APP 777/4885EPHX2 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.